Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Melanosis Clear all
Completed Phase 4 Interventional

Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma

NCT00469183
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Los Angeles, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 6, 2026, 8:35 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

RASopathy Biorepository

NCT04395495
View directory record Official record
Conditions
RAS Mutation, Neurofibromatosis 1, Noonan Syndrome, Noonan Syndrome With Multiple Lentigines, Noonan Neurofibromatosis Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome, Legius Syndrome, Smith-Kingsmore Syndrome, MTOR Gene Mutation, GATOR-1 Gene Mutation, SYNGAP1-Related Intellectual Disability, DLG4, MAPK1 Gene Mutation
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2065
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 6, 2026, 8:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluation of an Herbal-Based De-Pigmenting System

NCT02138539
View directory record Official record
Conditions
Melasma, Hyperpigmentation
Interventions
Herbal depigmenting agent (Epionce), Hydroquinone
Other · Drug
Lead sponsor
Sadick Research Group
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 6, 2026, 8:35 PM EDT
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 6, 2026, 8:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging

NCT04137263
View directory record Official record
Conditions
Melasma
Interventions
DOSE formulation
Other
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 6, 2026, 8:35 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy

NCT00771355
View directory record Official record
Conditions
Vitiligo, Melasma, Hyperpigmentation, Hypopigmentation
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Sep 6, 2026, 8:35 PM EDT
Completed Phase 2 Interventional

Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel

NCT00239135
View directory record Official record
Conditions
Keratosis
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 6, 2026, 8:35 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Lutronic PicoPlus Exploratory Clinical Trial

NCT03415685
View directory record Official record
Conditions
Tattoo; Pigmentation, Melasma, Benign Pigmented Lesion
Interventions
PicoPlus laser system
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Newport Beach, California • Elmhurst, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 6, 2026, 8:35 PM EDT
Completed Phase 2 Interventional

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

NCT00375739
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Huntsville, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Sep 6, 2026, 8:35 PM EDT
Completed No phase listed Observational

Hereditary Colorectal and Associated Tumor Registry Study

NCT00633607
View directory record Official record
Conditions
Lynch Syndrome, FAP, Hereditary Diffuse Gastric Cancer, Juvenile Polyposis Syndrome, Peutz-Jeghers Syndrome
Interventions
Research Registry
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 100 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 6, 2026, 8:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Polypodium Leucotomos for Melasma

NCT01162850
View directory record Official record
Conditions
Melasma
Interventions
Polypodium Leucotomos, Placebo
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Sep 6, 2026, 8:35 PM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma

NCT00472966
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 6, 2026, 8:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Single-Center 2-Arm Study for Lentigines on the Hands

NCT02763072
View directory record Official record
Conditions
Lentigines
Interventions
Enlighten Laser, Excel V Laser
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
30 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 6, 2026, 8:35 PM EDT
Terminated Phase 4 Interventional Results available

Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma

NCT00669071
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%, Cetaphil® Moisturizing Cream as Inactive Control
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 74 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
La Jolla, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 6, 2026, 8:35 PM EDT
Withdrawn Phase 2 Interventional

Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation

NCT06473974
View directory record Official record
Conditions
Facial Hyperpigmentation
Interventions
Test cosmetic product
Drug
Lead sponsor
Kayuraeffect, LLP
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Miami Lakes, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 6, 2026, 8:35 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma

NCT06415435
View directory record Official record
Conditions
Melasma
Interventions
Radiofrequency Microneedling
Device
Lead sponsor
Benev Company, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
La Jolla, California • Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 6, 2026, 8:35 PM EDT
Completed Phase 2 Interventional

Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans

NCT06940895
View directory record Official record
Conditions
Acanthosis Nigricans
Interventions
Sirolimus 0.2%
Drug
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 6, 2026, 8:35 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Oral Tranexamic Acid and Laser for Treatment of Melasma

NCT03686787
View directory record Official record
Conditions
Melasma
Interventions
Tranexamic Acid
Drug
Lead sponsor
Laser and Skin Surgery Center of New York
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 6, 2026, 8:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia

NCT01125150
View directory record Official record
Conditions
Acanthosis Nigricans, Hyperinsulinemia, Spectroscopic Analysis
Interventions
Metformin, Dietary Modification
Drug · Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
11 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Sep 6, 2026, 8:35 PM EDT
Terminated Phase 2 Interventional Results available

Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome

NCT00811590
View directory record Official record
Conditions
Peutz-Jeghers Syndrome
Interventions
Everolimus
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 6, 2026, 8:35 PM EDT
Completed Phase 3 Interventional Results available

Adjunctive Metformin Therapy in Double Diabetes

NCT01334125
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
10 Years to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Sep 6, 2026, 8:35 PM EDT
Recruiting No phase listed Observational

Neurocutaneous Melanocytosis Registry

NCT04548817
View directory record Official record
Conditions
Cutaneous Melanocytic Neoplasm, Large Cutaneous Melanocytic Nevi, Neurocutaneous Melanocytosis
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 6, 2026, 8:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cancer of the Pancreas Screening Study (CAPS 3)

NCT00438906
View directory record Official record
Conditions
Pancreatic Neoplasm, Peutz-Jeghers Syndrome
Interventions
Biopsy, Fine Needle Aspiration (FNA), Secretin (human synthetic) - ChiRhoClin
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 6, 2026, 8:35 PM EDT
Withdrawn Phase 1 Interventional

Spironolactone for the Treatment of Melasma

NCT03953209
View directory record Official record
Conditions
Melasma
Interventions
Spironolactone 50Mg Tablet, Spironolactone 100Mg Tablet, Spironolactone 200Mg
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 6, 2026, 8:35 PM EDT